Galera Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 1.44
Market capitalization 46.74M
Operating cash flow -46.93M
ESG Scores unknown

Company description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.59M 77k 1.2M -101k
Total Cashflows From Investing Activities -59.04M -27.82M 36.55M 5.24M
Net Borrowings 20M 20M 20M 57.5M
Total Cash From Financing Activities 89.84M 78.03M 20.51M 66.71M
Change To Operating Activities -701k -1.36M 2.71M -2.53M
Issuance Of Stock 58.03M 58.03M 506k 9.21M
Net Income -23.68M -51.93M -74.22M -80.53M
Change In Cash 8.64M 3.54M -2.48M 3.99M
Effect Of Exchange Rate
Total Cash From Operating Activities -22.17M -46.66M -59.54M -67.96M
Depreciation 127k 267k 368k 778k
Change To Account Receivables
Other Cashflows From Financing Activities
Change To Netincome 860k 5.66M 10.4M 14.43M
Capital Expenditures -347k -633k -457k -283k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 18.66M 42.33M 54.84M 52.42M
Income Before Tax -23.9M -51.94M -74.23M -80.53M
Net Income -23.68M -51.93M -74.22M -80.53M
Selling General Administrative 5.59M 8.36M 15.71M 20.95M
Gross Profit
Ebit -24.25M -50.69M -70.55M -73.37M
Operating Income -24.25M -50.69M -70.55M -73.37M
Interest Expense -220k -3.03M -4.88M -7.19M
Income Tax Expense -223k -9k -16k
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet 356k -1.25M -3.68M -7.17M
Net Income From Continuing Ops -23.68M -51.93M -74.22M -80.53M
Net Income Applicable To Common Shares -29.59M -59.11M -74.22M -80.53M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 26.97M 53.77M 77.98M 141.31M
Total Stockholder Equity -104.82M 69.61M 6.12M -58M
Other Current Liabilities
Total Assets 88.06M 123.38M 84.1M 83.31M
Common Stock 25k 25k 26k
Other Current Assets
Retained Earnings -104.82M -161.35M -235.57M -316.1M
Treasury Stock 3k 38k 12k -14k
Cash 14.81M 18.36M 15.87M 19.86M
Total Current Liabilities 6.44M 9.69M 13.97M 12.94M
Other Stockholder Equity 3k 38k 12k -14k
Property, Plant, and Equipment 568k 1.75M 1.55M 823k
Total Current Assets 83.85M 117.57M 77.93M 77.39M
Net Tangible Assets -107.96M 66.47M 2.98M -61.14M
Net Receivables 870k
Accounts Payable 3.87M 3.94M 5.15M 5.04M


Insider Transactions

Here are the insider transactions of stock shares related to Galera Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BEARDSLEY ROBERT AConversion of Exercise of derivative security at price 1.07 per share.D2022-11-21Chief Operating Officer10k
BEARDSLEY ROBERT AConversion of Exercise of derivative security at price 1.07 per share.D2022-09-12Chief Operating Officer10k
ALLEVA LAWRENCE MStock Gift at price 0.00 per share.D2022-07-18Director4k
BEARDSLEY ROBERT AConversion of Exercise of derivative security at price 1.07 per share.D2021-12-17Chief Operating Officer20k
WEST LINDAPurchase at price 2.74 per share.D2021-12-17Director20k
HOLMLUND JON TSale at price 8.47 per share.D2021-09-01Officer47.76k
HOLMLUND JON TConversion of Exercise of derivative security at price 2.43 per share.D2021-09-01Officer47.76k
WEST LINDAPurchase at price 9.13 per share.D2021-06-15Director10k
WEST LINDAPurchase at price 8.65 per share.D2021-06-02Director10k
ALLEVA LAWRENCE MPurchase at price 8.59 per share.I2021-06-01Director4.04k
WEST LINDAPurchase at price 8.64 per share.D2021-06-01Director20k
SORENSEN J. MELConversion of Exercise of derivative security at price 1.07 - 1.14 per share.D2021-03-26Chief Executive Officer217.01k
NOVO HOLDINGS A/SSale at price 10.58 per share.D2021-02-18Beneficial Owner of more than 10% of a Class of Security500k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Galera Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Galera Therapeutics Inc

Here is the result of two systematic investment strategies applied to Galera Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Galera Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Galera Therapeutics Inc:

Galera Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -83.06% on the backtest period.

Performance at glance

Performance

-83.06 %

Latent gain

-843.1 $

Invested capital

1015.1 $

Annualized return

-39.18 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Galera Therapeutics Inc

This is the result of two momentum investment strategies applied to Galera Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Galera Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Galera Therapeutics Inc:

Galera Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -82.16% of return on Galera Therapeutics Inc. That represents -2684.41$ of latent gain with 3267.49$ of employed capital.
  • The second momentum investment strategy would give -81.64% of return on Galera Therapeutics Inc. That represents -1223.4$ of latent gain with 1498.6$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-82.16 %

Latent gain

-2684.41 $

Invested capital

3267.49 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-81.64 %

Latent gain

-1223.4 $

Invested capital

1498.6 $

Annualized return

-49.78 %

Momentum equity curve on Galera Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Galera Therapeutics Inc:

Galera Therapeutics Inc momentum equity

Note: the dividends potentially given by Galera Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Galera Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Galera Therapeutics Inc since the beginning:

Galera Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Galera Therapeutics Inc

Buy the dip entry openings on Galera Therapeutics Inc

Galera Therapeutics Inc

The performance achieved by the robo-advisor on Galera Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Galera Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Galera Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Galera Therapeutics Inc

The following chart shows the result of the investment strategy applied to Galera Therapeutics Inc:

Galera Therapeutics Inc

Note: the dividends potentially given by Galera Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Galera Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Galera Therapeutics Inc:

Galera Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Galera Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Galera Therapeutics Inc.

Equity curve comparison on Galera Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Galera Therapeutics Inc investment strategy comparison

Employed capital comparison on Galera Therapeutics Inc

Galera Therapeutics Inc investment comparison

Performance comparison on Galera Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -83.06% -843.1$ 1015.1$ -39.18%
Momentum 1 quarter -82.16% -2684.41$ 3267.49$ -43.7%
Momentum 2 quarters -81.64% -1223.4$ 1498.6$ -49.78%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-39.18 %

Momentum 1Q

-49.78 %

Momentum 2Q

-49.78 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Galera Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Galera Therapeutics Inc

  • Most correlated stocks last 3 months

  • PHX ENERGY SERVICES CORP.
  • VAST RESOURCES PLC ORD 0.1P
  • Galera Therapeutics Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • INTELLIPHARMACEUTICS INTERNATIONAL INC
  • Beyond Meat Inc

  • Note: The algorithm computes the probability of correlation between Galera Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Galera Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Galera Therapeutics Inc
    Country United States
    City Malvern
    Address 2 West Liberty Boulevard
    Phone 610 725 1500
    Website www.galeratx.com
    FullTime employees 30
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker GRTX
    Market www.nasdaq.com

    Galera Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown